Comparative outcomes of 77 pregnancies, stratified based on antiphospholipid antibody related history
| History of OAPS with/without TAPS | History of TAPS with/without OAPS | History of OAPS and TAPS | History of OAPS versus TAPS (excluding those with both) | History of APS | |||||||||||
| Yes (n=33) | No (n=44) | P value | Yes (n=49) | No (n=28) | P value | Yes (n=24) | No (n=53) | P value | OAPS only (n=9) | TAPS only (n=25) | P value | Yes (n=58) | No (n=19) | P value | |
| TLD (n=36) | 17 (52%) | 19 (43%) | 0.4 | 22 (45%) | 14 (50%) | 0.8 | 12 (50%) | 24 (45%) | 1.0 | 5 (56%) | 10 (40%) | 0.4 | 27 (47%) | 9 (47%) | 1.0 |
| PTLD (n=12) | 4 (12%) | 8 (18%) | 0.5 | 7 (14%) | 5 (18%) | 0.7 | 3 (13%) | 9 (17%) | 0.4 | 1 (11%) | 4 (16%) | 1.0 | 8 (14%) | 4 (21%) | 0.4 |
| FD* (n=9) | 3 (9%) | 6 (14%) | 0.7 | 5 (10%) | 4 (14%) | 0.7 | 2 (8%) | 7 (13%) | 0.6 | 1 (11%) | 3 (12%) | 1.0 | 6 (10%) | 3 (16%) | 0.6 |
| EPL (n=20) | 9 (27%) | 11 (25%) | 1.0 | 15 (31%) | 5 (18%) | 0.2 | 7 (29%) | 13 (25%) | 0.3 | 2 (22%) | 8 (32%) | 0.6 | 17 (29%) | 3 (16%) | 0.3 |
| Composite pregnancy morbidity (n=14) | 5 (15%) | 9 (20%) | 0.7 | 8 (16%) | 6 (21%) | 0.7 | 3 (13%) | 11 (21%) | 0.5 | 2 (22%) | 5 (20%) | 1.0 | 10 (17%) | 4 (21%) | 0.7 |
*two fetal deaths associated with anomalies: 1 triple X syndrome (47 XXX) at 21 weeks, 1 cystic fibrosis at 20 weeks.
APS, antiphospholipid syndrome; APS, antiphospholipid syndrome; EPL, early pregnancy loss; FD, fetal death; LDA, low-dose aspirin; LMWH, low-molecular-weight heparin; OAPS, obstetric APS; PTLD, preterm live delivery; TAPS, thrombotic APS; TLD, term live delivery.